Saturday, October 29, 2016 9:18:15 AM
I truly don't hope an acquisition will materialize. $10-15 right now would be a disappointment.
A partnership deal would make sense and be beneficial. FDA approval for EPP seems like a shoe in and after the pre-NDA meeting in November the Vitiligo program should get more attention. Clinuvel has stated numerous times that the EPP and Vitiligo programs are intertwined in the US, most likely meaning that a majority of the data package with regard to safety etc. will be the groundwork in a forthcoming NDA for Vitiligo. Therefore, the submission of an NDA for EPP at a stage where everyone anticipates the FDA to approve also constitutes a good opportunity for a partner to come in and take the lead on Vitiligo.
The chairman has been touting an enlargement of the "group" lately and I believe that a such is imminent. The question is which form it will take.
The recent rise in share price is nice but does in no way reflect the true value of this company. A buyout would be tragic. A partner would be welcomed.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM